retatrutide clinical trials netherlands Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage trial, the company announced Retatrutide approval: FDA status, clinical

Retatrutide 120 MG USA The difference is in how it works

Consult your healthcare provider before making any treatment decisions

In a 49-page decision issued December 31, the Lehigh County Court of Common Pleas concluded that the plaintiff failed to satisfy four of the five requirements for class certification under Pennsylvania law

For many gastrointestinal conditions, probiotic benefits typically emerge after 48 weeks of continuous use, though evidence specifically for metabolic outcomes remains limited

Large observational studies have suggested lower rates of cognitive decline and dementia among people using GLP-1 medications compared with other diabetes treatments